Highlights

  • Pathkey.AI (ASX:PKY) share price was AUD 0.033, reflecting a 2.94% decline with a movement of AUD 0.0010 at the time of writing on 7 August 2026.
  • The company completed the acquisition of Chipforge, an AI-driven semiconductor hardware design and development technology platform.
  • Chipforge is focused on automating custom chip design and semiconductor development through an integrated workflow.
  • Pathkey.AI reported cash of $3.41 million as at 30 June 2026 while continuing development of its Chipforge and TrialKey platforms.

At the time of writing on 7 August 2026, Pathkey.AI (ASX:PKY) share price was AUD 0.033, reflecting a 2.94% decline with a movement of AUD 0.0010 on the day. The company’s market activity is being assessed alongside its expansion into artificial intelligence-driven technology platforms, including semiconductor design automation and clinical trial software solutions.

Pathkey.AI is an ASX-listed technology company focused on agentic artificial intelligence architecture and software platforms. The company is developing solutions designed to automate complex processes across different industries, with current activities focused on semiconductor technology and healthcare-related applications.

Chipforge Acquisition Expands Semiconductor Technology Strategy

A major development during the June 2026 quarter was the completion of Pathkey.AI’s acquisition of 100% of Chipforge, an AI-driven semiconductor hardware design and development technology platform.

The acquisition expands Pathkey.AI’s technology portfolio into semiconductor design automation. Chipforge is focused on streamlining custom chip development by integrating artificial intelligence capabilities into the semiconductor design process.

Traditional semiconductor development involves multiple stages, including architecture design, verification, optimisation, and engineering review. Chipforge aims to combine these activities into a more automated workflow, potentially reducing complexity in custom chip development processes.

AI-Powered Custom Chip Design Platform Development

Pathkey.AI reported that Chipforge is focused on automating custom semiconductor development and chip design through an integrated platform.

The technology is designed to support the development of specialised chips for applications requiring tailored computing capabilities. These areas include emerging technology fields where purpose-built hardware may be required to support specific workloads.

The company continues to integrate and develop the Chipforge platform as part of its broader artificial intelligence strategy.

Industry Engagement and Edge Silicon Applications

Following the acquisition, Pathkey.AI entered into a memorandum of understanding with Inturai Ventures Corp to explore the development of drone swarm command and control capabilities using Chipforge’s AI-powered chip design platform.

The proposed application involves building specialised edge silicon solutions designed for distributed systems. Edge computing refers to processing data closer to where it is generated rather than relying entirely on centralised cloud infrastructure.

The engagement highlights potential applications of AI-driven chip design technology in emerging areas such as autonomous systems and connected devices.

TrialKey Platform Commercialisation Progress

Alongside semiconductor activities, Pathkey.AI continues to develop and commercialise TrialKey, its clinical trial technology platform.

The company reported ongoing commercialisation of the clinical trial vertical, with increasing revenue generation and continued platform development.

TrialKey is designed to support clinical trial processes through technology-based solutions, addressing areas such as workflow management and operational efficiency within healthcare research environments.

Financial Position and Research Investment

Pathkey.AI reported cash holdings of $3.41 million as at 30 June 2026.

The company continues to participate in the Research and Development Tax Incentive Program, which provides potential cash offsets for eligible research and development activities conducted across both the Chipforge and TrialKey platforms.

Maintaining access to funding remains important for technology companies developing new platforms, as research, engineering, and commercialisation activities require continued investment.

Market Focus and Investor Considerations

Investors monitoring Pathkey.AI are likely to focus on the integration of Chipforge, progress in AI semiconductor development, commercial growth of TrialKey, and the company’s ability to convert technology platforms into scalable business opportunities.

The company’s strategy combines artificial intelligence development with industry-specific applications across semiconductor and healthcare technology markets.

Future updates regarding platform development, customer engagement, and commercial adoption will provide additional insight into the company’s progress.

Conclusion

Pathkey.AI continues to expand its artificial intelligence technology portfolio through the Chipforge acquisition and ongoing TrialKey commercialisation activities. The company’s focus on AI-driven semiconductor design automation and healthcare technology platforms represents a multi-sector approach to technology development. Future market attention is expected to remain on platform integration, industry partnerships, and commercial progress across its business segments.